Prime Medicine (PRME) Income towards Parent Company (2021 - 2026)

Prime Medicine has reported Income towards Parent Company for 6 years, with the latest figure at -$49.6 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 4.35% year-over-year to -$49.6 million; the trailing twelve-month figure through Mar 2026 stood at -$202.6 million (changed 0.28% YoY), and the FY2025 full-year result was -$204.2 million, down 4.25% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$49.6 million, down from -$47.5 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$23.8 million in Q1 2022, with the low at -$65.6 million in Q4 2023.
• Historically, Income towards Parent Company has averaged -$45.3 million across 5 years, with a median of -$47.5 million in 2025.
• The largest YoY upside for Income towards Parent Company was 37.54% in 2022 against a maximum downside of 78.83% in 2022.
• Prime Medicine's Income towards Parent Company stood at -$39.3 million in 2022, then slumped by 67.1% to -$65.6 million in 2023, then soared by 35.6% to -$42.3 million in 2024, then slipped by 12.42% to -$47.5 million in 2025, then fell by 4.44% to -$49.6 million in 2026.
• The last three Income towards Parent Company figures came in at -$49.6 million (Q1 2026), -$47.5 million (Q4 2025), and -$52.8 million (Q3 2025), per Business Quant data.